The Drug Enforcement Administration's telemedicine special registration, first proposed in January 2025, is still not final. In its place, the DEA and the Department of Health and Human Services have relied on a fourth temporary extension of the COVID-era telemedicine prescribing flexibilities, published December 31, 2025 and in effect through December 31, 2026. For a physician who prescribes controlled substances by telemedicine, and for the pharmacy that fills that prescription, the gap between a temporary extension and a final rule is the live compliance question.
The Fourth Temporary Extension, Through December 31, 2026
The extension published at 90 FR 61301 is effective January 1, 2026 through December 31, 2026, under DEA Docket No. DEA-407. It is the fourth time DEA and HHS have extended the telemedicine prescribing flexibilities first adopted during the COVID-19 public health emergency, following earlier extensions in 2023 and November 2024. Under the fourth extension, a DEA-registered practitioner may prescribe Schedule II through V controlled substances by telemedicine without a prior in-person medical evaluation, subject to the conditions the rule sets out. The extension keeps the pandemic-era flexibility in place. It does not create a permanent telemedicine prescribing pathway, and it does not depend on the special registration proposal described below.
The Special Registration Rule Remains Proposed, Not Final
DEA published the special registration proposal, Special Registrations for Telemedicine and Limited State Telemedicine Registrations, on January 17, 2025, at 90 FR 6541. The proposed rule would create three categories of special registration, letting a qualifying practitioner prescribe controlled substances by telemedicine without ever conducting an in-person evaluation, subject to added recordkeeping and reporting conditions under the proposal's expanded DEA recordkeeping. Public comments closed March 18, 2025. As of this writing, the Federal Register shows no final rule under that docket. Until DEA publishes one, general telemedicine prescribing of controlled substances without a prior in-person exam runs on the temporary extension, not on the proposed special registration framework; DEA and HHS have separately finalized narrower telemedicine rules for buprenorphine treatment of opioid use disorder and for care of Department of Veterans Affairs patients, both effective December 31, 2025.
The Pharmacy's Corresponding Responsibility on a Telemedicine Script
A pharmacist filling a prescription that originated from a telemedicine encounter carries the same corresponding responsibility as on any other controlled substance prescription. Under 21 CFR 1306.04(a), responsibility for a legitimate prescription rests with the prescriber, but a corresponding responsibility rests with the pharmacist who fills it. A pharmacist cannot treat a valid-looking telemedicine prescription as self-verifying. A telemedicine practice whose prescribing pattern, geography, or diagnosis mix does not match an ordinary in-person practice is a red flag the pharmacist is expected to resolve before dispensing, extension or no extension. DEA scrutiny of a pharmacy's corresponding-responsibility practices can escalate to an order to show cause or, in urgent cases, an immediate suspension order, the same registration consequences a physician's own telemedicine practice can face after a DEA inspection.
The temporary extension keeps telemedicine prescribing of controlled substances in effect through December 31, 2026; it does not make the proposed special registration rule the law.
Why Early Legal Counsel Is Critical
It is critical that physicians and pharmacies promptly retain experienced healthcare defense counsel upon receiving a subpoena, audit notice, investigative request, or other government inquiry tied to telemedicine prescribing of controlled substances. Early legal intervention can protect the provider's rights, ensure appropriate responses to DEA requests, avoid inadvertent admissions, preserve relevant defenses, and allow counsel to communicate with investigators on the provider's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the provider to unnecessary risk, particularly while the underlying rule is still in flux.
How Health Law Alliance Can Help
Health Law Alliance defends physicians and pharmacies in DEA registration matters that turn on telemedicine prescribing of controlled substances, including matters where corresponding responsibility or an order to show cause is already in motion. Health Law Alliance's attorneys have overseen 2,000+ audits and handled 5,000+ matters, with 25+ years of experience. If your practice or pharmacy is facing DEA scrutiny over telemedicine prescribing, contact Health Law Alliance's DEA defense attorneys for a free, confidential consultation.
